Mitochondrial protein plays key role in glioblastoma and therapeutic resistance
Glioblastoma is the most common type of brain tumor that affects adults and, unfortunately, still remains incurable. In a new study, researchers have demonstrated that a specific mitochondrial protein plays an important role in glioblastoma, and can therefore be used as a potential target to reduce tumors.
“Glioblastoma is notorious for its lethality. One of the major challenges is that it spreads invasively throughout the brain. We’re interested in understanding what drives this process in order to identify new therapeutic strategies,” said Brendan Harley (RBTE leader/EIRH), the Robert W. Schaefer Professor of Chemical and Biomolecular Engineering.
In the current study, the researchers focused on the mitochondrial coiled-coil-helix-coiled-coil-helix domain containing protein 2 — also known as CHCHD2. The complicated name refers to the structure of the protein, whose subunits are coiled together like rope strands.
The researchers first looked at The Cancer Genome Atlas glioblastoma database to see whether they could spot any patterns that related CHCHD2 levels to cancer. Out of 577 samples, they found that the CHCHD2 genes had higher expression in tumor cells, compared to non-tumor tissue, and was higher in advanced cases of glioblastoma.
“We also learned that in humans the gene encoding CHCHD2 was closely linked to the gene encoding the epidermal growth factor receptor, or EGFR, on chromosome 7. A mutated version of this protein is found in over 50% of glioblastoma patients,” said Rex Gaskins (RBTE), the Keith W. and Sara M. Kelley Endowed Professor of Immunophysiology in Animal Sciences and corresponding author of the study.
When the results from the database showed that CHCHD2 expression was highest in the patients who harbored the mutation known as EGFRvIII, the researchers realized that understanding the interaction between these two proteins can be crucial to understanding glioblastoma progression.
To confirm their hypothesis, the researchers looked at the effects of CHCHD2 on tumor growth in mice. They compared mice that had CHCHD2 and the mutated version of EGFR to mice that did not contain CHCHD2, but still had mutated EGFR. The first group of mice survived for an average of 17 days, whereas the second group survived for 25 days. The researchers found that the mice that died earlier had more tumor growth infiltrating the surrounding brain tissue.


